<DOC>
	<DOCNO>NCT02938910</DOCNO>
	<brief_summary>Animal model demonstrate role aldosterone leave ventricular remodel involve fibrosis , apoptosis hypertrophy . Myocardial fibrosis risk factor serious arrhythmia sudden death ischemic idiopathic hypertrophic heart disease . It accept patient primary aldosteronism high prevalence LV hypertrophy , arterial involvement increase cardiovascular risk . In human , link demonstrate aldosterone heart failure well benefit administration anti -aldosterone drug lower mortality population , regardless blood pressure level . The administration spironolactone ( aldosterone ) hypertensive rat prevent occurrence aortic fibrosis . Plasma aldosteronism human associated inflammation , fibrosis aortic stiffness . However , primary aldosteronism generally associate so-called secondary hypertension . Chronic hypertension alone recognize etiological factor myocardial hypertrophy ( myocardial fibrosis advance ) . The purpose study investigate effect MRI hyperaldosteronism heart .</brief_summary>
	<brief_title>Study Myocardial Interstitial Fibrosis Hyperaldosteronism</brief_title>
	<detailed_description>Cross-sectional study double analysis ( A B ) 2 x 2 sub-groups ( ratio control/case 1/1 ) - clinical situation : subject hypertensive . 20 subject primary aldosteronism compare 20 patient essential arterial hypertension - clinical situation normotensive subject , 20 subject secondary aldosteronism loss congenital salt ( Bartter 's syndrome / Gitelman ) compare 20 healthy volunteer . Controls ( essential hypertension healthy volunteer ) match age , sex body size two experimental group ( HAP Gitelman ) . All subject recruit CIC European Georges Pompidou Hospital ( Paris ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hyperaldosteronism</mesh_term>
	<criteria>Patients primary hyperaldosteronism : Aldosterone / renin plasma ratio SUP 64 pmol / mU aldosterone semisitting position SUP 500pmol / l aldosteronuria &gt; 63nmol/24h , Both neutral treatment least 15 day ( alphablocker , calcium channel blocker , central inhibitor ) . BMI = 35 kg / m² . For patient secondary hyperaldosteronism : Documented diagnosis detection mutation ( ) homozygous compound heterozygous gene SLC12A3 encode CLCNKB chloride channel , gene encode HTSC NaCl cotransport thiazide sensitive . Normal blood pressure ( mean three consecutive measurement SBP INF 140 mmHg DBP INF 90 mmHg measure semisitting position 5 minute rest ) . For hypertensive patient : Hypertension diagnose average three consecutive BP measurement = 140 / = 90 mmHg supine position 5 minute rest average daytime PA SUP 135/85 mmHg ambulatory blood pressure monitoring ( ABPM ) selfmeasurement , presence one antihypertensive medication regardless BP level . No argument secondary hypertension ( renal artery stenosis , hypermineralocorticoidism , pheochromocytoma , iatrogenic ... ) negative balance secondary hypertension . BMI &lt; 35 kg/m2 . For healthy subject : Normal blood pressure ( mean three consecutive measurement SBP INF 140 mmHg DBP INF 90 mmHg measure semisitting position 5 minute rest ) . Absence HA know detected determination carry study ( see criterion PAHs ) . BMI &lt; 35 kg / m² Laboratory test ( hematological biochemical blood test , urinalysis , serology Research toxic ) within normal limit clinically acceptable age sex .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Primary hyperaldosteronism</keyword>
	<keyword>Secondary hyperaldosteronism</keyword>
	<keyword>Cardiac fibrosis</keyword>
	<keyword>magnetic resonance imaging</keyword>
</DOC>